OcuCure Therapeutics
Total Raised
$3.85MInvestors Count
1Funding, Valuation & Revenue
11 Fundings
OcuCure Therapeutics has raised $3.85M over 11 rounds.
OcuCure Therapeutics's latest funding round was a Unattributed - X for $0.1M on May 4, 2017.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/4/2017 | Unattributed - X | $0.1M | Undisclosed Investors | 1 | ||
10/6/2015 | Unattributed - IX | $0.2M | Undisclosed Investors | 1 | ||
2/26/2014 | Unattributed - VIII | $0.13M | Undisclosed Investors | 1 | ||
7/1/2013 | Unattributed - VII | |||||
6/21/2011 | Unattributed - VI |
Date | 5/4/2017 | 10/6/2015 | 2/26/2014 | 7/1/2013 | 6/21/2011 |
|---|---|---|---|---|---|
Round | Unattributed - X | Unattributed - IX | Unattributed - VIII | Unattributed - VII | Unattributed - VI |
Amount | $0.1M | $0.2M | $0.13M | ||
Investors | Undisclosed Investors | Undisclosed Investors | Undisclosed Investors | ||
Valuation | |||||
Revenue | |||||
Sources | 1 | 1 | 1 |
OcuCure Therapeutics Investors
1 Investors
OcuCure Therapeutics has 1 investors. Carilion Biomedical Institute invested in OcuCure Therapeutics's Other Investors funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
1 Other Investors | Other | Virginia |
First funding | |
|---|---|
Last Funding | |
Investor | |
Rounds | 1 Other Investors |
Board Seats | |
Type | Other |
Location | Virginia |
Compare OcuCure Therapeutics to Competitors
Phylogix is an early-stage pharmaceutical company developing chemoprotectant compounds.
NeurOp, Inc. is a clinical-stage biotechnology company focused on developing medicines for central nervous system (CNS) disorders. The company offers drug candidates aimed at treating conditions such as pain, stroke, subarachnoid hemorrhage, and treatment-resistant depression, primarily through the modulation of NMDA receptors in the brain. NeurOp's products target the GluN2B subunit of these receptors. It is based in Atlanta, Georgia.
Intarcia Therapeutics is a biotech company that focuses on the development of biologics and peptides for the treatment of cardio-renal-metabolic diseases. The company's main offerings include a pipeline of long-acting GLP-1 receptor agonists and other peptide-based therapies designed to improve the management of chronic diseases. Intarcia primarily serves sectors in the healthcare industry that are involved with chronic disease management and biopharmaceuticals. It was founded in 1995 and is based in Boston, Massachusetts.
Kanisa Pharmaceuticals is a pharmaceutical company focused on the acquisition, development and commercialization of therapeutics in the field of oncology.
Total Pharmaceutical Care, Inc. offers home healthcare and infusion therapy services
believe a chemical cocktail invented by Dr. Phil Campbell (who aims to serve as an advisor to the company), a professor at the Baylor College of Dentistry, can soothe millions of mouths and make this early-stage pharmaceutical company millions of dollars. A doub
Loading...